{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T18:17:40Z","timestamp":1790014660416,"version":"4.0.1"},"reference-count":26,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2016,4,1]],"date-time":"2016-04-01T00:00:00Z","timestamp":1459468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Therapies"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1016\/j.therap.2016.02.008","type":"journal-article","created":{"date-parts":[[2016,3,18]],"date-time":"2016-03-18T14:32:30Z","timestamp":1458311550000},"page":"161-169","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Pharmacovigilance in Europe: Place of the Pharmacovigilance Risk Assessment Committee (PRAC) in organisation and decisional processes"],"prefix":"10.1016","volume":"71","author":[{"given":"Marie-Laure","family":"Laroche","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnaud","family":"Batz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9l\u00e8ne","family":"G\u00e9niaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corinne","family":"F\u00e9chant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis","family":"Merle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Maison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.therap.2016.02.008_bib0005","series-title":"20th anniversary of EMA","author":"European Medicines Agency","year":"2015"},{"key":"10.1016\/j.therap.2016.02.008_bib0010","year":"2015"},{"key":"10.1016\/j.therap.2016.02.008_bib0015","series-title":"Directive 2004\/27\/CE du parlement europ\u00e9en et du conseil du 31\u00a0mars 2004\u00a0modifiant la directive 2001\/83\/CE instituant un code communautaire relatif aux m\u00e9dicaments \u00e0 usage humain (JOCE no\u00a0L. 136\u00a0du 30\/4\/2004)","year":"2015"},{"key":"10.1016\/j.therap.2016.02.008_bib0020","series-title":"Directive 2001\/83\/CE du parlement europ\u00e9en et du conseil du 6\u00a0novembre 2001\u00a0instituant un code communautaire relatif aux m\u00e9dicaments \u00e0 usage humain (JOCE no\u00a0L. 311\u00a0du 28\/11\/2001)","year":"2015"},{"key":"10.1016\/j.therap.2016.02.008_bib0025","series-title":"Pharmacovigilance: Good pharmacovigilance practices","author":"European Medicines Agency","year":"2015"},{"key":"10.1016\/j.therap.2016.02.008_bib0030","year":"2015"},{"key":"10.1016\/j.therap.2016.02.008_bib0035","series-title":"Directive 2010\/84\/UE du parlement europ\u00e9en et du conseil du 15\u00a0d\u00e9cembre 2010\u00a0modifiant, en ce qui concerne la pharmacovigilance, la directive 2001\/83\/CE instituant un code communautaire relatif au m\u00e9dicament \u00e0 usage humain (JOUE no\u00a0L. 348\u00a0du 31\/12\/2010)","year":"2015"},{"key":"10.1016\/j.therap.2016.02.008_bib0040","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.meddro.2012.06.001","article-title":"Le renforcement du syst\u00e8me de pharmacovigilance de l\u2019Union europ\u00e9enne (Analyse du nouveau cadre r\u00e9glementaire issu des dispositions de la directive 2010\/84\/UE et du r\u00e8glement [UE] no\u00a01235\/2010)","volume":"115","author":"Chemtob Conc\u00e9","year":"2012","journal-title":"Med Droit"},{"key":"10.1016\/j.therap.2016.02.008_bib0045","first-page":"107","article-title":"La pharmacovigilance europ\u00e9enne\u00a0: aspects r\u00e9glementaires","volume":"29","author":"Dhanani","year":"2000","journal-title":"Presse Med"},{"key":"10.1016\/j.therap.2016.02.008_bib0050","series-title":"Pharmacovigilance Risk Assessment Committee (PRAC)","author":"European Medicines Agency","year":"2015"},{"key":"10.1016\/j.therap.2016.02.008_bib0055","series-title":"Coordination Group for Mutual Recognition and Decentralised Procedures\u00a0\u2013\u00a0Human. (CMDh)","author":"European Medicines Agency","year":"2015"},{"key":"10.1016\/j.therap.2016.02.008_bib0060","series-title":"Heads of Medicines Agencies. About CMDh","year":"2015"},{"key":"10.1016\/j.therap.2016.02.008_bib0065","series-title":"Committee for Medicinal Products for Human Use (CHMP)","author":"European Medicines Agency","year":"2015"},{"key":"10.1016\/j.therap.2016.02.008_bib0070","series-title":"CHMP overview","author":"European Medicines Agency","year":"2015"},{"key":"10.1016\/j.therap.2016.02.008_bib0075","series-title":"CHMP: rules of procedure","author":"European Medicines Agency","year":"2015"},{"key":"10.1016\/j.therap.2016.02.008_bib0080","series-title":"PRAC: overview","author":"European Medicines Agency","year":"2015"},{"key":"10.1016\/j.therap.2016.02.008_bib0085","series-title":"PRAC: rules of procedure","author":"European Medicines Agency","year":"2015"},{"key":"10.1016\/j.therap.2016.02.008_bib0090","series-title":"PRAC recommendations on safety signals","author":"European Medicines Agency","year":"2015"},{"key":"10.1016\/j.therap.2016.02.008_bib0095","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1007\/s40264-014-0240-1","article-title":"A description of signals during the first 18\u00a0months of the EMA pharmacovigilance risk assessment committee","volume":"37","author":"Pacurariu","year":"2014","journal-title":"Drug Saf"},{"key":"10.1016\/j.therap.2016.02.008_bib0100","series-title":"Referral procedures","author":"European Medicines Agency","year":"2015"},{"key":"10.1016\/j.therap.2016.02.008_bib0105","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1038\/nrd3713-c1","article-title":"Proactively managing the risk of marketed drugs: experience with the EMA Pharmacovigilance Risk Assessment Committee","volume":"13","author":"Arlett","year":"2014","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.therap.2016.02.008_bib0110","series-title":"Periodic safety update reports","author":"European Medicines Agency","year":"2015"},{"key":"10.1016\/j.therap.2016.02.008_bib0115","series-title":"Risk management plans","author":"European Medicines Agency","year":"2015"},{"key":"10.1016\/j.therap.2016.02.008_bib0120","series-title":"Post-authorisation safety studies: questions and answers","author":"European Medicines Agency","year":"2015"},{"key":"10.1016\/j.therap.2016.02.008_bib0125","doi-asserted-by":"crossref","first-page":"187","DOI":"10.2165\/11586620-000000000-00000","article-title":"Strengthening and rationalizing pharmacovigilance in the EU: where is Europe heading to? A review of the new EU legislation on pharmacovigilance","volume":"34","author":"Borg","year":"2011","journal-title":"Drug Saf"},{"issue":"Suppl.\u00a01","key":"10.1016\/j.therap.2016.02.008_bib0130","first-page":"1","article-title":"The U.S. Food and Drug Administration's Mini-Sentinel program: status and direction","volume":"21","author":"Platt","year":"2012","journal-title":"Pharmacoepidemiol Drug Saf"}],"container-title":["Therapies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595716000275?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595716000275?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,4,3]],"date-time":"2019-04-03T11:52:14Z","timestamp":1554292334000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0040595716000275"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,4]]}},"alternative-id":["S0040595716000275"],"URL":"https:\/\/doi.org\/10.1016\/j.therap.2016.02.008","relation":{},"ISSN":["0040-5957"],"issn-type":[{"value":"0040-5957","type":"print"}],"subject":[],"published":{"date-parts":[[2016,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacovigilance in Europe: Place of the Pharmacovigilance Risk Assessment Committee (PRAC) in organisation and decisional processes","name":"articletitle","label":"Article Title"},{"value":"Therapies","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.therap.2016.02.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.therap.2015.10.001","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Soci\u00e9t\u00e9 fran\u00e7aise de pharmacologie et de th\u00e9rapeutique. Published by Elsevier Masson SAS All rights reserved.","name":"copyright","label":"Copyright"}]}}